A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis

A Bergqvist, Bergqvist A, SCANDET Group
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2000 · vol. 14(6) , pp. 425–32 · doi:10.3109/09513590009167714 · PMID:11228063
RCT OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study found no statistically significant differences in treatment results or side effects between goserelin and nafarelin in 213 women with endometriosis over a 6-month period.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effects of goserelin and nafarelin were compared in a prospective, randomized, open, parallel study of 6 months' treatment of 252 women with symptomatic, laparoscopically proven endometriosis. Twenty-eight departments of obstetrics and gynecology in Sweden, Norway, Denmark and Finland were included. Evaluations were made every 3 months for quantification of pain, bleeding and adverse events and convenience of treatment, and at 3 months after the end of treatment, when a control laparoscopy was performed for evaluation of changes in endometriotic lesion size, color and location. Thirty-nine patients withdrew and 113 women given goserelin and 100 women given nafarelin completed the study. There were no statistically significant differences between the groups, either in adverse events or in bleeding. There were no correlations between location, lesion size or type of lesion, and symptom score in either group, or between treatments with regard to change in endometriosis score. In both groups, the percentage of red and black lesions was reduced while the proportion of white lesions increased. The pain score was significantly reduced in both groups. Local irritation in the nasal mucosa was reported in both groups, mostly in the nafarelin-treated group. The goserelin-treated group also reported local symptoms at the injection site. We conclude that there is no statistically significant difference in treatment results or side-effects between goserelin and nafarelin when used for the treatment of endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Goserelin Hormones Nafarelin Administration, Intranasal Administration, Intranasal Adolescent Adolescent Adult Adult Endometriosis Endometriosis Endometriosis Estradiol Estradiol Estradiol Female Female Follicle Stimulating Hormone Follicle Stimulating Hormone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Source provenance

crossref
last seen: 2026-08-23T06:29:35.501816+00:00
europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
pubmed
last seen: 2026-10-08T20:59:46.244316+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine